In addition, PSA gene, which is a specific marker for prostate cancer under AR transcriptional control, results similarly upregulated upon β-HCH and testosterone treatment, whereas its mRNA levels decrease when cells are pre-treated with the AR antagonist bicalutamide. Here, KLK3 is linked to prostate carcinoma.